Renovatio

What Renovatio does

Renovatio Clinical is a multispecialty clinical research organization headquartered in Houston, Texas, operating three community-based clinical research centers across Texas (Houston headquarters, The Woodlands, and El Paso). Founded in 2014 (per firmographics; the company cites 20+ years of combined team experience rather than a specific founding date), Renovatio provides Phase I-IV site services for pharmaceutical sponsors and contract research organizations (CROs), with stated coverage across hematology, oncology, pulmonology, cardiology, rheumatology, and urology. The company reports 180+ trials completed, 4 FDA-approved drugs resulting from completed trials, and a network of 100+ industry partners spanning major pharmaceutical sponsors (e.g., AbbVie, Amgen, AstraZeneca, Genentech, Johnson & Johnson, Takeda, Pfizer, Novartis, Bristol-Myers Squibb, Sanofi, Eli Lilly, Regeneron, GSK, Boehringer Ingelheim, BeiGene, Incyte, Astellas, Seagen) and large CROs (IQVIA, Parexel, ICON, Syneos Health, PPD, MedPace). Its primary value proposition is fast study startup (often under two weeks) and patient-centric trial execution.

The core offering is an integrated clinical-trial service stack rather than a discrete software product. Service modules include clinical trial management, patient recruitment and retention (with population research, screening, community/physician outreach, scheduling, and a 24/7 support line), site initiation and management, quality and compliance (dedicated QA team, SOPs, HIPAA/regulatory compliance, training), contract management (budgets, negotiation, invoicing, patient reimbursement), laboratory capabilities (dedicated lab space, specialized equipment and storage, sample processing, imaging access, calibration), and a multi-therapeutic investigator network with national and international connections. The technology layer consists of third-party EDC and clinical research systems (Medidata Rave, Oracle Clinical RDC, Oracle InForm, iDataFax, Clin'Form, Cenduit, eResearch Technology, nSpire, iCardiac) and central-laboratory integrations with LabCorp, Quest Diagnostics, Covance, PPD, and Icon. No proprietary AI/ML capability, software platform, patent, trademark, or API/SDK offering is disclosed.

Renovatio operates as a private, for-profit entity led by Founder and CEO Talal A. Kayyal, MD, MPH, with a disclosed headcount range of 1-10 (firmographics) and no reported external investors, funding rounds, M&A activity, or parent organization. Revenue is generated through project-based contractual engagements with sponsors and CROs; pricing is quote-based and not publicly disclosed. Go-to-market is enterprise B2B direct sales targeting sponsors and CROs via a formal strategic partnership program, supplemented by a physician-investor recruitment funnel and direct-to-patient/community outreach through the corporate website, LinkedIn, YouTube, Facebook, and Instagram. Operating geographies are restricted to Texas/USA, with no disclosed international facility footprint.

Name

Renovatio

Legal name

Renovatio Clinical

Website

https://renovatioclinical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Renovatio Clinical is a multispecialty clinical research organization operating three community-based research centers in Texas, providing Phase I-IV clinical trial site services for pharmaceutical sponsors and CROs across oncology, hematology, pulmonology, cardiology, rheumatology, and urology.

Ownership category

akta.pro rank

Product category

Clinical Research Organization (CRO) Site Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Clinical trial management
• Clinical research site services
• Patient recruitment services
• Pharmaceutical trial execution
• Contract research organization

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Trial Services: Renovatio Clinical generates revenue by providing clinical trial management services to pharmaceutical sponsors and CROs. Services include trial startup, execution, patient recruitment, site management, regulatory compliance, and data collection. Revenue is generated through contractual agreements for research services across Phase I-IV trials.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Renovatio Clinical is a multispecialty clinical research organization that delivers end-to-end clinical trial management services for pharmaceutical sponsors and CROs, spanning Phase I–IV interventional and observational studies. Core offerings cover trial startup, patient recruitment, site initiation and management, quality and compliance, contract management, on-site laboratory capabilities, and a multi-therapeutic investigator network, executed across three community-based research centers in Texas (Houston, The Woodlands, El Paso) under a patient-centric, fast-startup model.

Product overview

Renovatio is a multispecialty clinical research organization offering a unified platform of clinical research services rather than discrete software products. The core offering consists of integrated service modules including Clinical Trial Management (Phase I-IV, interventional and observational), Patient Recruitment Services, Site Initiation & Management, Quality & Compliance Services, Contract Management, Laboratory Capabilities, and a Trial Investigator Network. The company operates three community clinical research centers and has completed over 180 trials resulting in 4 FDA-approved drugs. Services are delivered through an experienced research team including full-time physicians, clinical research experts, and lab technicians, all supported by integrations with major EDC systems (Medidata Rave, Oracle Clinical RDC, Oracle InForm) and central laboratory partners (Covance, Quest, LabCorp, PPD, Icon). The platform emphasizes fast study startups (often under two weeks) and a patient-centric approach to clinical trial execution.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Management Services End-to-end clinical trial management services covering Phase I through Phase IV interventional and observational studies, including protocol assessment, feasibility studies, and full trial execution for pharmaceutical sponsors and CROs.
• Patient Recruitment Services Patient recruitment and retention services including population research, screening, enrollment, community and physician outreach, visit scheduling with reminders, and a 24/7 patient support line for clinical trial sponsors and CROs.
• Site Initiation & Management Site identification, readiness assessment, pre-study and qualification visits, and ongoing site operationalization and management for clinical trial locations used by pharmaceutical sponsors and CROs.
• Quality & Compliance Services Dedicated quality team services including data collection and reporting, standard operating procedures, HIPAA and regulatory compliance, and training, development, and certification programs for clinical trial clients.
• Contract Management Contract management services including budget negotiation and approval, contract agreement and support, customer relationship management, invoicing, and patient reimbursement services for clinical trial sponsors and CROs.
• Laboratory Capabilities On-site laboratory capabilities providing dedicated lab space, specialized equipment and storage, sample processing and logistics, access to imaging facilities, and equipment calibration and maintenance services for clinical trial sponsors.
• Community-Based Clinical Research Community-based outpatient and inpatient clinical trials conducted across Renovatio's three community clinical research centers in Texas (Houston HQ, The Woodlands, El Paso), providing access to diverse patient populations in oncology, hematology, pulmonology, cardiology, and rheumatology.
• Investigator Network Multi-therapeutic network of qualified principal investigators spanning multiple therapeutic areas with national and international connections, enabling physicians to incorporate clinical research into their practices or participate in ongoing clinical trials.

Quantifiable outcome

• Fast study startups in less than two weeks
• +2 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration14 records

Feature4 records

Partnerships

33 partnerships are on record, tiered core and supporting.

• AbbViecoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution. Renovatio conducts clinical trials on behalf of AbbVie for drug development programs.
• AmgencoreStrategic or Co-development PartnerPharmaceutical sponsor partner. Currently conducting trials including DELLPHI-306 (limited-stage small-cell lung cancer).
• AstraZenecacoreStrategic or Co-development PartnerPharmaceutical sponsor partner with extensive trial history including CALLA study for cervical cancer.
• GenentechcoreStrategic or Co-development PartnerPharmaceutical sponsor partner. Currently conducting GLOBRYTE trial for relapsed/refractory mantle cell lymphoma.
• Johnson & JohnsoncoreStrategic or Co-development PartnerPharmaceutical sponsor partner. Currently conducting COPERNICUS trial for EGFR-mutated non-small cell lung cancer.
• TakedacoreStrategic or Co-development PartnerPharmaceutical sponsor partner. Currently conducting TAK-113-4002 trial for colorectal cancer.
• PfizercoreStrategic or Co-development PartnerPharmaceutical sponsor partner with trial history including rituximab biosimilar studies.
• NovartiscoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• Bristol-Myers SquibbcoreStrategic or Co-development PartnerPharmaceutical sponsor partner with multiple oncology trials conducted.
• SanoficoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• Eli LillycoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• RegeneroncoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• GSKcoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• Boehringer IngelheimcoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• BeiGenecoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• IncytecoreStrategic or Co-development PartnerPharmaceutical sponsor partner with trials including CITADEL studies for lymphoma.
• Janssen Research & DevelopmentcoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• AstellascoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• SeagencoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• GenmabcoreStrategic or Co-development PartnerPharmaceutical sponsor partner for clinical trial execution.
• LabCorpsupportingTechnology or IntegrationCentral laboratory partner for sample processing, providing diagnostic and laboratory services for clinical trials.
• CovancesupportingTechnology or IntegrationCentral laboratory partner and CRO providing lab services and clinical trial support.
• IQVIAcoreStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• ParexelcoreStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• ICONcoreStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• Syneos HealthcoreStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• PPDcoreStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• MedPacecoreStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• ClinipacesupportingStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• WCG ClinicalsupportingTechnology or IntegrationClinical services partner providing IRB and governance support.
• ClinchoicesupportingStrategic or Co-development PartnerCRO partner for clinical trial management and execution.
• Medidata (Dassault Systèmes)supportingTechnology or IntegrationTechnology partner providing Medidata Rave EDC system certification and support for data capture.
• Thermo Fisher ScientificsupportingTechnology or IntegrationLaboratory and equipment partner for clinical research operations.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• MedPace: MedPace is a midsize global CRO focused on Phase I-IV trials across multiple therapeutic areas including oncology — listed as a Renovatio partner CRO and a direct competitor for sponsor trial placements.
• Syneos Health: Syneos is a large global clinical research and commercial services organization with site-network reach — comparable incumbent CRO that Renovatio partners with and competes against for sponsor placement.
• IQVIA: IQVIA is the largest global CRO and operates an extensive site network along with EDC and central lab services that Renovatio partners with — sets the baseline of scale and capability that Renovatio competes against.
• ICON plc: ICON is a top-3 global CRO offering full-service clinical trial management across all phases and therapeutic areas — a broad incumbent competitor for sponsor contracts Renovatio's site network supports.

Direct peers

• Flourish Research: Flourish Research is a multispecialty clinical trial site network running trials across multiple therapeutic areas for pharma and CRO sponsors — directly comparable in site-network model and sponsor-relationship orientation.
• Accel Research Sites: Accel is a multispecialty clinical research site network operating Phase I-IV trials across multiple U.S. locations with therapeutic breadth similar to Renovatio's oncology/hematology/pulmonology/cardiology mix.
• Velocity Clinical Research: Velocity operates a multispecialty community-based clinical research site network across the U.S. conducting Phase I-IV trials for pharma sponsors — directly comparable to Renovatio's community-based trial center model and sponsor mix.
• Javara Research: Javara is an embedded multispecialty clinical research site network that integrates trials into community physician practices — closely aligned with Renovatio's investigator-network-plus-own-sites model serving pharma sponsors.
• Elligo Health Research: Elligo brings clinical research directly into community healthcare settings using its Goes Direct® model, providing multi-therapeutic site services to sponsors — a comparable decentralized/site-network approach to Renovatio.

Others

• WCG Clinical: WCG provides clinical trial technology, IRB review, and site enablement services to sponsors, CROs, and research sites — a supporting infrastructure partner that Renovatio uses for IRB/governance support across its trials.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Renovatioclinical
• Facebookfacebook.com/RenovatioClinicalHouston
• LinkedInlinkedin.com/company/renovatio-clinical-consultants
• Instagraminstagram.com/renovatioclinical

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renovatio